Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa

Kanerva, Riitta; Rissanen, Alla; Sarna, Seppo

doi:10.3109/08039489509011912

Cited by 25 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, fluoxetine (60 mg/day) administered for between 8 and16 weeks led to significant reductions in binge eating in most 14,16,17,21 but not all studies. 13,19 Fluoxetine (60 mg/day) also performed significantly better than fluoxetine (20 mg/day) in decreasing binge eating. 16 No effect of fluoxetine (60 mg/day) compared with placebo was observed in the one study in which patients were already receiving intensive inpatient psychotherapy.…”

Section: Medication Trials For Bulimia Nervosamentioning

confidence: 99%

See 1 more Smart Citation

Bulimia nervosa treatment: A systematic review of randomized controlled trials

Shapiro

Berkman

Brownley

et al. 2007

Intl J Eating Disorders

387

174

View full text Add to dashboard Cite

Evidence for medication or behavioral treatment for BN is strong, for self-help is weak; for harms related to medication is strong but either weak or nonexistent for other interventions; and evidence for differential outcome by sociodemographic factors is nonexistent. Attention to sample size, standardization of outcome measures, attrition, and reporting of abstinence from target behaviors are required. Longer follow-up intervals, innovative treatments, and attention to sociodemographic factors would enhance the literature.

show abstract

Section: Medication Trials For Bulimia Nervosamentioning

confidence: 99%

“…13 Fluoxetine had mixed results on depression and anxiety. Some studies showed greater efficacy than placebo in decreasing depression scores, 16,19 whereas others did not. 13,14,17,21 Romano et al explored the efficacy of fluoxetine (60 mg/day) versus placebo in preventing relapse of BN over 52 weeks.…”

Section: Medication Trials For Bulimia Nervosamentioning

confidence: 99%

Bulimia nervosa treatment: A systematic review of randomized controlled trials

Shapiro

Berkman

Brownley

et al. 2007

Intl J Eating Disorders

387

174

View full text Add to dashboard Cite

show abstract

“…Eight‐week trials by Kanerva et al, Beaumont et al, and Romano et al also showed improvement in symptoms of bulimia. 47 , 49 , 59 Sixty milligrams of fluoxetine was better than 20 mg in these studies. In a 4‐week trial by Fichter et al, fluoxetine 60 mg did not differentiate from placebo, although this could have been a result of the short duration of the trial 40 …”

Section: Bulimia Nervosamentioning

confidence: 60%

“…Sixteen of the 20 studies reviewed are antidepressant trials. [39][40][41]43,44,[46][47][48][49][50][51][52][53]54,59,63 Seven of those trials involve fluoxetine, 3 desipramine, 1 trazodone, 1 brofaromine, 2 fluvoxamine, 1 moclobemide, and 1 citalopram.…”

Section: Antidepressantsmentioning

confidence: 99%

Pharmacotherapy of Eating Disorders

2010

View full text Add to dashboard Cite

Eating disorders are complex, chronic disorders that are difficult to treat. In addition, the 2 primary eating disorders, anorexia nervosa and bulimia nervosa, may have acute, life-threatening consequences. Medication trials for eating disorders have been hampered by high dropout rates, high placebo response, short trial duration, insufficient doses, and difficult outcome measures. Only 1 medication has been FDA approved for any eating disorder to date, and that is for fluoxetine in the treatment of bulimia. Clearly, new large-scale, independent studies using novel agents, and studying the use of medications for both short- and long-term outcomes, are needed.

show abstract

“…Two studies were multi‐centre, multinational [16,17], both comparing fluoxetine to placebo. Ten trials were conducted in the USA [18–27], two in Canada [28,29], one in the UK [30] and one in Norway [31]. Trials recruited outpatients seeking treatment ‘spontaneously’ from eating disorders clinics or programs, or included also volunteers for research recruited through advertisement.…”

Section: Resultsmentioning

confidence: 99%